Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca and Bristol-Myers Squibb expand Onglyza labelling

AstraZeneca and Bristol-Myers Squibb expand Onglyza labelling

7th March 2011

AstraZeneca and Bristol-Myers Squibb have expanded the labelling of their dipeptidyl peptidase-4 inhibitor Onglyza to address the needs of a wider range of diabetes patients.

The drug has been approved by the European Commission for the treatment of adult type 2 diabetes patients suffering from moderate or severe renal impairment, making it the first therapy of its kind to be ratified for this group.

This decision was granted on the basis of data from a recent placebo-controlled study, which demonstrated the safety and efficacy of the drug in this specification.

Onglyza is currently available in the EU as a means of improving glycaemic control among diabetes patients and has been submitted for regulatory approval in more than 87 countries.

It is used in combination with metformin, sulphonylurea, or thiazolidinedione in instances where each treatment alone cannot deliver the appropriate level of glycaemic regulation.

Last month, the company received EU backing to launch Fluenz, a nasally-administered live attenuated influenza vaccine for children.ADNFCR-8000103-ID-800445698-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.